Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer

Opinion
Video

Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
1 expert in this video
1 expert in this video
1 expert in this video
Related Content